Labcorp announces new test offering to detect Alzheimer's disease pathology in both primary and specialty care settings
Labcorp now offers Roche’s Elecsys pTau-217 test, an FDA-cleared blood test that detects amyloid pathology linked to Alzheimer's in individuals aged 55 and older, providing a minimally invasive diagnostic option.
Labcorp will offer Roche’s Elecsys pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA), according to an announcement. The blood test aids in identifying amyloid pathology associated with Alzheimer's disease in individuals 55 and older with signs, symptoms or complaints of cognitive decline.
Elecsys pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings
Key features of the Elecsys pTau-217 test:
Uses the same clinical cutoffs across primary and specialty care settings, providing a standardized approach to patient assessment.
Provides positive, intermediate and negative result categories to support assessment of the likelihood of amyloid pathology.
Offers a convenient, minimally invasive blood-based testing option with performance comparable to cerebrospinal fluid (CSF) testing and positron emission tomography (PET) imaging.
Once ordered by a clinician, patients can have their blood drawn in a physician's office or at one of Labcorp's more than 2,200 patient service centers nationwide.
Results are interpreted alongside clinical information and other relevant findings as part of a comprehensive evaluation.
